Company profile for Takeda Pharmaceutical

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in over 230 years of distinguished history in Japan. We have presence in approximately 80 countries, with leading positions in Japan and the U.S., respectively the third...
Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in over 230 years of distinguished history in Japan. We have presence in approximately 80 countries, with leading positions in Japan and the U.S., respectively the third and first largest pharmaceutical markets in the world. We will deliver highly innovative medicines and transformative care for more people globally.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Japan
Address
Address
1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8668
Telephone
Telephone
+81 6 6204-2111
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

CPhI South East Asia

Not Confirmed

envelop Contact Supplier

CPhI South East Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

INTERVIEW #SpeakPharma

[Sponsored by another company]
Alchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets
With increasing flavour bans in key markets, vaping brands are facing significant challenges in providing satisfying alternatives to vapers and smokers looking to transition. Recognising this need, Alchem NicSelect™ is making a bold move by offering its key customers royalty-free and unrestricted geographical access to its revolutionary T-MAX™ technology.“At Alchem NicSelect™, we understand the urgency for vaping brands to adapt to new regulations without compromising on satisfaction. By offering royalty-free access to T-MAX™ technology, we empower our customers to provide the closest cigarette-like experience possible, even in markets with strict flavour restrictions,” said Riccardo Santambrogio, Europe Sales Manager.HIGHLIGHTS// offering royalty-free access to T-MAX™ technology/ unrestricted geographical access/ closest cigarette-like experience Addressing the biggest barrier: Nicotine satisfactionOne of the primary reasons many vapers are dissatisfied and smokers struggle to switch to vaping is that traditional nicotine solutions fail to replicate the rapid satisfaction provided by cigarettes. Nicotine replacement therapies (NRTs) and even conventional vaping products often lack the immediate nicotine hit, throat feel, and overall experience that smokers are accustomed to. T-MAX™ solves this problem by engineering a nicotine experience that closely mimics cigarette consumption without relying on flavours.T-MAX™ provides a unique 3-in-1 approach:1. The Speed of a Cigarette – Rapid nicotine delivery and rush within seconds for immediate satisfaction.2. The Power of Nicotine Salts – A stronger perceived nicotine effect without exceeding legal limits (20 mg/ml nicotine limit under the European Tobacco Products Directive). With T-MAX™, 8 mg/ml feels like 20 mg/ml, and 14 mg/ml feels like 40 mg/ml.3. The Throat Hit of Freebase Nicotine – Especially in a flavour-free formulation, the combined ingredients in T-MAX™ deliver an even more satisfying throat feel than expected from nicotine base, much closer to and more familiar with a cigarette throat feel that habitual smokers recognise.HIGHLIGHTS// unique 3-in-1 approach/ rush within seconds/ stronger perceived nicotine effect without exceeding legal limits/ more satisfying throat feel that habitual smokers recogniseNo flavour, but not less satisfyingWhile flavours have traditionally played a role in vaping adoption, market realities are shifting. With flavour bans spreading across regions, brands need solutions that deliver satisfaction without relying on taste. Consumer research has shown that T-MAX™ performs exceptionally well even without added flavours. Since most cigarette smokers do not smoke for the tobacco flavour but rather for the nicotine hit and habitual experience, T-MAX™ provides a viable alternative that aligns with new regulatory landscapes.HIGHLIGHTS// flavour bans spreading across regions/ T-MAX™ performs exceptionally well even without added flavoursEmpowering vape brands with free access to T-MAX™By granting customers royalty-free access to the T-MAX™ technology, Alchem NicSelect™ is removing barriers for vaping brands and original equipment manufacturers (OEMs) looking to adapt to regulatory changes. This open-access approach ensures that manufacturers can integrate T-MAX™ into their product lines without additional costs, allowing them to offer superior nicotine satisfaction in markets where flavours are no longer an option.HIGHLIGHTS// removing barriers for vaping brands and OEMs looking to adapt/ manufacturers can integrate T-MAX™ into product lines without additional costsThe future of vaping in restricted marketsWith T-MAX™, the vaping industry has a powerful tool to retain customers and convert smokers who have struggled with traditional vaping products. By delivering the key elements of cigarette satisfaction — without combustion or flavours — T-MAX™ is set to redefine what a satisfying vape experience means in a post-flavour-ban world.“Our commitment to innovation and accessibility means we are providing our customers with the solutions they need to navigate an evolving regulatory landscape. T-MAX™ allows brands to offer a highly satisfying experience that mimics smoking without relying on flavours. The message is clear: no flavour, but not less satisfying”, added Santambrogio.HIGHLIGHTS// powerful tool to retain customers and convert smokers/ delivering the key elements of cigarette satisfaction without combustion or flavours/ no flavour, but not less satisfying

Impressions: 1293

https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets

Radio Compass
06 May 2025

VLOG #PharmaReel

[Sponsored by another company]
This PharmaReel highlights Gentec Pharmaceutical's expertise in generic APIs, HPAPIs, and prostaglandins with more than 30 years of experience. Operating from EU-GMP-certified facilities, the company exports to over 70 countries worldwide.

Impressions: 99

read-more

DATA COMPILATION #PharmaFlow

[Sponsored by another company]
CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint
During the second quarter (Q2) of 2025, contract development and manufacturing organizations (CDMOs) made substantial investments in specialized therapeutic manufacturing. The quarter also saw CDMOs pursue high-value, complex manufacturing niches, particularly in antibody-drug conjugates (ADCs), cell and gene therapies (CGTs) and oligonucleotides.Alongside these trends, Q2 also saw CDMOs strengthen their footprint in the United States amid concerns over rising tariffs and unpredictable trade policies being enforced by the Trump administration.Regeneron Pharmaceuticals committed over US$ 3 billion through a 10-year agreement with Fujifilm Diosynth Biotechnologies to nearly double its US manufacturing capacity for biologics. Under this agreement, Fujifilm will manufacture and supply drug products for Regeneron at its large-scale facility in Holly Springs, North Carolina.Thermo Fisher Scientific announced plans to invest an additional US$ 2 billion in the US over four years, reinforcing its manufacturing and R&D capabilities. With 64 facilities spread across 37 states, Thermo Fisher aims to bolster American innovation and competitiveness. Similarly, Piramal Pharma announced a US$ 90 million investment plan for expanding two facilities in the US, thereby bringing its total investment in the country to US$ 570 million. View CDMO Activity Tracker for Q2 2025 (Free Excel Available)Veranova, Carbogen lead ADC wave; Axplora doubles down on HPAPI production in ItalyThe quarter saw substantial investments in ADC manufacturing. Veranova announced a US$ 20 million investment in bioconjugation development and cGMP manufacturing capacity at its Devens, Massachusetts campus. With this investment, Veranova will be able to provide a more comprehensive suite of services to its partners developing ADCs and other bioconjugates. Veranova’s total investment in the Devens facility now stands at over US$ 50 million. Swiss CDMO Carbogen announced a US$ 31 million co-investment with an unnamed Japanese investor to expand its capabilities across its Aarau and Neuland (Switzerland) facilities. The facility will address increasing demand for complex and high-value compounds such as ADC drug linkers.Axplora announced a further €35 million (US$ 41 million) expansion of its Farmabios site in Italy, doubling the facility to approximately 108,000 square meters by mid-2026. This investment raises its total spend on the site to over €80 million (US$ 94.05 million) since 2019, supporting the production of highly potent active pharmaceutical ingredients (HPAPIs). Farmabios now stands as a key hub in Axplora’s global CDMO network.Polish pharmaceutical manufacturer Polfa Tarchomin is positioning itself as a significant player in the European CDMO market through its investment in the Center for Development and Production of Highly Potent Drugs. This 12,000 square meter facility has two state-of-the-art production lines designed for filling vials and pre-filled syringes with an annual capacity of 26 million product units.Skyepharma’s projected annual revenues from oncology-linked activities touched €10 million (US$ 11.2 million). The CDMO’s facility in Saint-Quentin-Fallavier is equipped to handle cytotoxic and cytostatic compounds, and is one of the few facilities in France capable of managing HPAPIs for oral anticancer treatments. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Athena acquires Medipha Santé, Famar buys MiP Pharma’s German site to strengthen European footprintDuring the quarter, several CDMOs enhanced their strategic capabilities through M&As. Athena Pharmaceutiques acquired  Medipha Santé to build a fully integrated pharmaceutical services platform in Europe. Based in Paris, Athena has strengthened its commercial and regulatory toolbox by bringing aboard Medipha Santé’s 35-strong team, which supports over 100 partner organizations and files approximately 350 dossiers annually with ANSM and other European agencies. With this integration, Athena positions itself as a one-stop CDMO partner.With the acquisition of MiP Pharma’s sterile manufacturing site in Homburg, Germany, the Famar Group has expanded its capabilities in aseptic and lyophilized fill-and-finish operations. The acquisition has strengthened Famar’s position in sterile drug manufacturing. The CDMO now has seven manufacturing facilities in Europe.PCI Pharma Services’ acquisition of Ajinomoto Althea has established a world-class, large-scale manufacturing hub in the San Diego region with state-of-the-art aseptic facilities for prefilled syringes, cartridges and high-potent formulations such as ADCs. PCI Pharma is now amongst the few US-based CDMOs capable of comprehensive ADC manufacturing.Samsung Biologics’ strategic spinoff of its biosimilar business stood out as a significant corporate restructuring exercise during the quarter. The separation of Samsung Bioepis, tentatively renamed Samsung Epis Holdings, aims to enhance Samsung Biologics’ strategic focus and build client trust, as it eliminates potential conflicts between CDMO services and proprietary drug development. The move came after Samsung Biologics inked a contract worth 737.3 billion Korean won (US$ 518 million) with an undisclosed US pharmaceutical company.WuXi Biologics announced a US$ 167 million divestment of its German facility to Terumo and broke ground on a microbial production plant in China. National Resilience, which was launched five years ago as the US drug manufacturer dedicated to broadening access to medicines and protecting biopharma supply chains, said it is shuttering six of its 10 facilities. The company said the sites were “not being fully utilized.” View CDMO Activity Tracker for Q2 2025 (Free Excel Available) MilliporeSigma, Simtra form 5-year ADC alliance; Silexion partners Catalent for siRNA developmentMerck KGaA’s MilliporeSigma and Simtra struck a five-year strategic alliance, combining expertise across the ADC value chain to reduce development timelines and complexity for biopharmaceutical companies. Viralgen collaborated with Trogenix to rapidly scale product supply for TGX-007, an AAV gene therapy for glioblastoma (a type of cancer of the brain and spinal cord).  Silexion announced a collaboration with Catalent for small interfacing RNA (siRNA) development and manufacturing. Catalent’s Limoges (France) facility will conduct formulation development and clinical manufacturing for Silexion’s SIL204 candidate, supporting both systemic and intra-tumoral delivery formulations.Skyepharma’s collaboration with Eneapharm through the Skyehub platform aims to support the treatment of patients suffering from exocrine pancreatic insufficiency, including those affected by cystic fibrosis or pancreatic cancer. Orion Corporation reached an agreement with Shilpa Biocare for the distribution of recombinant human albumin in Europe.Meanwhile, Aenova announced the launch of its Aenovation program, an initiative designed to fast-track early development of pharmaceutical formulations. The program addresses the critical challenges of bioavailability and time-to-market faced by poorly soluble drug candidates. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Our view The quarter saw CDMO developments mimic the broader trends in the pharmaceutical industry, such as onshoring of critical manufacturing capabilities in the US, consolidation of specialized expertise through strategic partnerships, and the relentless focus on emerging therapeutic modalities that promise to transform patient care. With CDMOs continuing to invest in next-generation manufacturing capabilities, we expect the sector to play a crucial role in drug innovation. 

Impressions: 233

https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint

#PharmaFlow by PHARMACOMPASS
10 Jul 2025

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20250628336756/en/Takeda-Announces-U.S.-FDA-Approval-of-GAMMAGARD-LIQUID-ERC-the-Only-Ready-to-Use-Liquid-Immunoglobulin-Therapy-with-Low-Immunoglobulin-A-IgA-Content1

BUSINESSWIRE
30 Jun 2025

https://www.businesswire.com/news/home/20250623826419/en/Takeda-Announces-New-Assignments-of-Directors

BUSINESSWIRE
25 Jun 2025

https://www.businesswire.com/news/home/20250603992751/en/European-Commission-Approves-ADCETRIS-brentuximab-vedotin-for-the-Treatment-of-Adult-Patients-with-Newly-Diagnosed-Stage-IIbIIIIV-Hodgkin-Lymphoma-in-Combination-with-ECADD

BUSINESSWIRE
03 Jun 2025

https://www.businesswire.com/news/home/20250531031305/en/Protagonist-and-Takeda-Announce-ASCO-Plenary-Presentation-Highlighting-Full-32-Week-Results-from-Phase-3-VERIFY-Study-of-Rusfertide-Showing-Reductions-in-Phlebotomy-Improved-Hematocrit-Control-in-Polycythemia-Vera

BUSINESSWIRE
01 Jun 2025

https://www.businesswire.com/news/home/20250527716937/en/Takeda-and-Nature-Announce-Call-for-Applications-Now-Open-for-2026-Innovators-in-Science-Award

BUSINESSWIRE
27 May 2025

https://www.businesswire.com/news/home/20250508841747/en/The-New-England-Journal-of-Medicine-Publishes-Data-from-Phase-2b-Trial-of-Oral-Orexin-Receptor-2-Agonist-Oveporexton-TAK-861-in-People-with-Narcolepsy-Type-1

BUSINESSWIRE
14 May 2025

USDMF

read-more
read-more
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-more

01

EPS
Not Confirmed
arrow
arrow
EPS
Not Confirmed

Takeda Pharmaceutical

NDC Package Code : 11532-1453

Start Marketing Date : 1993-04-16

End Marketing Date : 2025-12-31

Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (15mg/mL)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank

02

EPS
Not Confirmed
arrow
arrow
EPS
Not Confirmed

Takeda Pharmaceutical

NDC Package Code : 11532-1452

Start Marketing Date : 1993-04-16

End Marketing Date : 2025-12-31

Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (11.25mg/mL)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank

03

EPS
Not Confirmed
arrow
arrow
EPS
Not Confirmed

Takeda Pharmaceutical

NDC Package Code : 11532-3662

Start Marketing Date : 1997-03-07

End Marketing Date : 2025-12-31

Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (11.25mg/1.5mL)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank

04

EPS
Not Confirmed
arrow
arrow
EPS
Not Confirmed

Takeda Pharmaceutical

NDC Package Code : 11532-3680

Start Marketing Date : 2010-08-23

End Marketing Date : 2025-12-31

Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (30mg/1.5mL)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank

05

EPS
Not Confirmed
arrow
arrow
EPS
Not Confirmed

Takeda Pharmaceutical

NDC Package Code : 11532-1451

Start Marketing Date : 1989-01-26

End Marketing Date : 2025-12-31

Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (7.5mg/mL)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank

06

EPS
Not Confirmed
arrow
arrow
EPS
Not Confirmed

Takeda Pharmaceutical

NDC Package Code : 11532-3338

Start Marketing Date : 1995-12-22

End Marketing Date : 2025-12-31

Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (22.5mg/1.5mL)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank

07

EPS
Not Confirmed
arrow
arrow
EPS
Not Confirmed

Takeda Pharmaceutical

NDC Package Code : 11532-1450

Start Marketing Date : 1990-10-22

End Marketing Date : 2025-12-31

Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (3.75mg/mL)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank

08

EPS
Not Confirmed
arrow
arrow
EPS
Not Confirmed

Takeda Pharmaceutical

NDC Package Code : 11532-1457

Start Marketing Date : 2011-08-15

End Marketing Date : 2025-12-31

Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (30mg/1.5mL)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank

09

EPS
Not Confirmed
arrow
arrow
EPS
Not Confirmed

Takeda Pharmaceutical

NDC Package Code : 11532-1456

Start Marketing Date : 2011-08-15

End Marketing Date : 2025-12-31

Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (11.25mg/1.5mL)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank

10

EPS
Not Confirmed
arrow
arrow
EPS
Not Confirmed

Takeda Pharmaceutical

NDC Package Code : 11532-1454

Start Marketing Date : 1993-04-16

End Marketing Date : 2025-12-31

Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (7.5mg/mL)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank
click full view

FDF Dossiers

read-more
read-more

01

Brand Name : Adrenalin

EPS
Not Confirmed
arrow

Brand Name : Adrenalin

arrow
EPS
Not Confirmed

Takeda Pharmaceutical

Dosage Form : Solution for injection

Brand Name : Adrenalin

Dosage Strength : 0.1mg/ml

Packaging : Ampoule av glass 10 5ml

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

02

Brand Name : Adrenalin

EPS
Not Confirmed
arrow

Brand Name : Adrenalin

arrow
EPS
Not Confirmed

Takeda Pharmaceutical

Dosage Form : Solution for injection

Brand Name : Adrenalin

Dosage Strength : 1mg/ml

Packaging : Ampoule av glass 10 1ml

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

03

Brand Name : Replagal

EPS
Not Confirmed
arrow

Brand Name : Replagal

arrow
EPS
Not Confirmed

Takeda Pharmaceutical

Dosage Form : INF

Brand Name : Replagal

Dosage Strength : 1mg/ml

Packaging : 3.5X1mg/ml

Approval Date :

Application Number :

Regulatory Info : Originator

Registration Country : South Africa

blank

04

Brand Name : REPLAGAL

EPS
Not Confirmed
arrow

Brand Name : REPLAGAL

arrow
EPS
Not Confirmed

Takeda Pharmaceutical

Dosage Form : SOLUTION

Brand Name : REPLAGAL

Dosage Strength : 1MG/ML

Packaging :

Approval Date :

Application Number : 2249057

Regulatory Info :

Registration Country : Canada

blank

05

Brand Name : Replagal

EPS
Not Confirmed
arrow

Brand Name : Replagal

arrow
EPS
Not Confirmed

Takeda Pharmaceutical

Dosage Form : Inf Conc

Brand Name : Replagal

Dosage Strength : 3.5mg/3.5ml

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

06

Brand Name : Allopurinol Nycomed

EPS
Not Confirmed
arrow

Brand Name : Allopurinol Nycomed

arrow
EPS
Not Confirmed

Takeda Pharmaceutical

Dosage Form : TABLET

Brand Name : Allopurinol Nycomed

Dosage Strength : 100 MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

07

Brand Name : Allopur

EPS
Not Confirmed
arrow

Brand Name : Allopur

arrow
EPS
Not Confirmed

Takeda Pharmaceutical

Dosage Form : Antic-calc Tablet

Brand Name : Allopur

Dosage Strength : 300 mg

Packaging : Box

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

08

Brand Name : Allopurinol Nycomed

EPS
Not Confirmed
arrow

Brand Name : Allopurinol Nycomed

arrow
EPS
Not Confirmed

Takeda Pharmaceutical

Dosage Form : TABLET

Brand Name : Allopurinol Nycomed

Dosage Strength : 300 MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

09

Brand Name : Allopur

EPS
Not Confirmed
arrow

Brand Name : Allopur

arrow
EPS
Not Confirmed

Takeda Pharmaceutical

Dosage Form : Antic-calc Tablet

Brand Name : Allopur

Dosage Strength : 100 mg

Packaging : Box

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

10

Brand Name : KAZANO

EPS
Not Confirmed
arrow

Brand Name : KAZANO

arrow
EPS
Not Confirmed

Takeda Pharmaceutical

Dosage Form : TABLET

Brand Name : KAZANO

Dosage Strength : 12.5MG

Packaging : 60

Approval Date :

Application Number : 2417219

Regulatory Info :

Registration Country : Canada

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

Inspections and registrations

Upload your audits for free, ask us

ABOUT THIS PAGE

Contact TAKEDA and get a quotation

TAKEDA is a supplier offers 37 products (APIs, Excipients or Intermediates).

Find a price of Leuprolide Acetate bulk with CEP offered by TAKEDA

Find a price of Pantoprazole Sodium bulk with CEP offered by TAKEDA

Find a price of Candesartan Cilexetil bulk with JDMF offered by TAKEDA

Find a price of Codeine bulk with JDMF offered by TAKEDA

Find a price of Codeine Phosphate bulk with JDMF offered by TAKEDA

Find a price of Leuprolide Acetate bulk with DMF offered by TAKEDA

Find a price of Morphine Hydrochloride bulk with JDMF offered by TAKEDA

Find a price of Noscapine bulk with JDMF offered by TAKEDA

Find a price of Ridaforolimus bulk with DMF offered by TAKEDA

Find a price of Succinylcholine Chloride bulk with CEP offered by TAKEDA

Find a price of Deproteinised hemoderivative of calf blood, Actovegin concentrate bulk with CEP offered by TAKEDA

Find a price of Azilsartan bulk offered by TAKEDA

Find a price of Cefmenoxime HCl bulk offered by TAKEDA

Find a price of Cefotiam bulk offered by TAKEDA

Find a price of Cefsulodin bulk offered by TAKEDA

Find a price of Estazolam bulk offered by TAKEDA

Find a price of Folic Acid bulk offered by TAKEDA

Find a price of Hydromorphone Hydrochloride bulk offered by TAKEDA

Find a price of Leuprolide Acetate bulk offered by TAKEDA

Find a price of O-Chloroacetylcarbamoyl-Fumagillol bulk offered by TAKEDA

Find a price of Oxendolone bulk offered by TAKEDA

Find a price of Pyridoxine Hydrochloride bulk offered by TAKEDA

Find a price of Sodium Carbonate bulk offered by TAKEDA

Find a price of PROCESSING OF OXENDOLONE AQUOSUSPENSOID INJ IN THE OSAKA PLANT bulk offered by TAKEDA

Find a price of FACILITIES AND OPERATING PROCEDURES IN HIKARI-CITY, YAMAGUCHI, JAPAN bulk offered by TAKEDA

Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN SHONAN PLANT. bulk offered by TAKEDA

Find a price of TAK-603 bulk offered by TAKEDA

Find a price of TAP-144-SR(N) 7.5 AND 3.75 MG. bulk offered by TAKEDA

Find a price of SODIUM DEACETYL CEPHALOSPORIN C (DCPE-Na) PRODUCTION IN HIKARI PLANT bulk offered by TAKEDA

Find a price of EM574 bulk offered by TAKEDA

Find a price of Alogliptin Benzoate bulk offered by TAKEDA

Find a price of Dexlansoprazole bulk offered by TAKEDA

Find a price of Lansoprazole bulk offered by TAKEDA

Find a price of Pioglitazone Hydrochloride bulk offered by TAKEDA

Find a price of Roflumilast bulk offered by TAKEDA

Find a price of Vedolizumab bulk offered by TAKEDA

Find a price of Vonoprazan Fumarate bulk offered by TAKEDA

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty